Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 3/20 | 0.33 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.32 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 4/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.30 |
| ▸ | CES1 | P23141 | 2/20 | 0.30 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13192953 | 1.00 | ACLY (0.37) | ACLYKIF11SOAT2SOAT1MAOA | |
| SCHEMBL13192936 | 1.00 | ACLY (0.37) | ACLYKIF11SOAT2SOAT1MAOA | |
| SCHEMBL13192504 | 1.00 | ACLY (0.37) | ACLYKIF11SOAT2SOAT1MAOA | |
| SCHEMBL17787829 | 0.96 | ACLY (0.35) | ACLYKIF11SOAT2SOAT1MAOA | |
| SCHEMBL13192491 | 0.91 | KIF11 (0.38) | KIF11MAOAMAPT | |
| SCHEMBL13930235 | 0.90 | KIF11 (0.39) | KIF11MAOAMAPT | |
| SCHEMBL13192948 | 0.87 | ACLY (0.38) | ACLYSOAT2SOAT1FAAHEPHX2 | |
| SCHEMBL13193020 | 0.87 | ACLY (0.38) | ACLYSOAT2SOAT1FAAHEPHX2 | |
| SCHEMBL13192983 | 0.87 | ACLY (0.38) | ACLYSOAT2SOAT1FAAHEPHX2 | |
| SCHEMBL15686629 | 0.87 | ACLY (0.38) | ACLYSOAT2SOAT1FAAHEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9422318-B2 | Epoxyeicosatrienoic acid analogs and methods of making and using the same | THE MEDICAL COLLEGE OF WISCONSIN, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| EP-2694470-B1 | EPOXYEICOSATRIENOIC ACID ANALOGS AND METHODS OF MAKING AND USING THE SAME | WISCONSIN MED COLLEGE INC (US) | 2016-06-01 | — | — | EP | disclosed |
| US-20150336916-A1 | EPOXYEICOSATRIENOIC ACID ANALOGS AND METHODS OF MAKING AND USING THE SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-11-26 | — | — | US | disclosed |
| US-9127027-B2 | Epoxyeicosatrienoic acid analogs and methods of making and using the same | THE MEDICAL COLLEGE OF WISCONSIN, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-20140113884-A1 | EPOXYEICOSATRIENOIC ACID ANALOGS AND METHODS OF MAKING AND USING THE SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-04-24 | — | — | US | disclosed |
| WO-2012138706-A1 | EPOXYEICOSATRIENOIC ACID ANALOGS AND METHODS OF MAKING AND USING THE SAME | MCW RESEARCH FOUNDATION, INC. (US) | 2012-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336916-A1 | EPOXYEICOSATRIENOIC ACID ANALOGS AND METHODS OF MAKING AND USING THE SAME | PTGER1, PTGES, PTGER2 | ACLY 1999/4885KIF11 4664/4885SOAT2 183/4885 |
| US-20140113884-A1 | EPOXYEICOSATRIENOIC ACID ANALOGS AND METHODS OF MAKING AND USING THE SAME | PTGER1, PTGES, PTGER2 | ACLY 1999/4885KIF11 4664/4885SOAT2 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.